ReviewFrontiers in neurology2025
Pathophysiology, clinical manifestations, and prognostic insights of cerebral fat embolism: a literature review.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral fat embolism (CFE) syndrome, a rare and often incomplete variant of fat embolism syndrome (FES), is characterized by pure neurological involvement and may occur after both traumatic and nontraumatic events. It is typically caused by embolization of fat droplets into the systemic circulation, most commonly after orthopedic trauma. The clinical presentation ranges from subtle neurological symptoms to life-threatening events, including respiratory distress, altered mental status, seizures, and coma. Diagnosis is challenging due to nonspecific signs, concurrent injuries, and lack of definitive diagnostic criteria. Although the Gurd and Wilson and Modified Gurd criteria are widely used, they are not fully validated and may not capture the full clinical picture. Neuroimaging, particularly MRI, plays a key supportive role. Despite investigations into corticosteroids and other pharmacologic agents, no treatment has demonstrated definitive efficacy. Thus, management remains largely supportive. Therefore, prompt recognition, refinement of diagnostic criteria, and further research into reliable biomarkers and targeted therapies are essential for improving CFE outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.